Oncology Diagnostics Panel Session

Part 3 of our latest series discusses how the emergence of Immuno-Oncology has impacted the Oncology Diagnostics landscape.

The Impact of I/O on Oncology Diagnostics


  • Shailesh Maingi – Founder and CEO, Kineticos

Panel Members

  • Eric Mayer – CEO, EDP Biotech
  • Sandra Dunn – CEO, Phoenix Molecular
  • Brian Kelly – Global Director, Diagnostic Partnering, Thermo Fisher

Subscribe to Kineticos to receive weekly emails containing insightful content.